Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

The present invention relates to a process for preparing a compound having the following formula (II):

F—SO.sub.2—N.sup.−—SO.sub.2—R.sub.1NH.sub.4.sup.+  (II)

wherein R.sub.1 represents F or a linear or branched alkyl radical, substituted with at least one fluorine atom, said process comprising a step of bringing an anhydrous flow F1 comprising ammonia (NH.sub.3) into contact with a compound of formula (I):

F—SO.sub.2—NH—SO.sub.2—R.sub.1  (I)

R.sub.1 is as defined above.

The present invention relates to a process for preparing a compound having the following formula (II):

F—SO.sub.2—N.sup.−—SO.sub.2—R.sub.1NH.sub.4.sup.+  (II)

wherein R.sub.1 represents F or a linear or branched alkyl radical, substituted with at least one fluorine atom, said process comprising a step of bringing an anhydrous flow F1 comprising ammonia (NH.sub.3) into contact with a compound of formula (I):

F—SO.sub.2—NH—SO.sub.2—R.sub.1  (I)

R.sub.1 is as defined above.

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.

The present application relates to compounds with NLRP.sub.3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3inhibition.

The present application relates to compounds with NLRP.sub.3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP.sub.3inhibition.

The present disclosure provides a chlorhexidine-cyclamate complex having a formula [C.sub.22H.sub.32Cl.sub.2N.sub.10][C.sub.6H.sub.12NO.sub.3S].sub.2 having antibacterial and antiplaque properties, together with oral care compositions comprising the complex, and methods of making and using these complexes and compositions.

The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at −30° C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50° C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises anon-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound. ##STR00001##

The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at −30° C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50° C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises anon-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound. ##STR00001##